Publications

1. Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L, Piwnica-Worms D, Hewitt S, Udupi GM, Gallagher WM, Wegner C, West BL, Wang-Gillam A, Goedegebuure P, Linehan, DC and DeNardo, DG. (2013). Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses. Cancer Research, 73(3):1128-1141.

2. Rexhepaj E, Agnarsdóttir M, Bergman J, Edqvist P-H, Bergqvist M, Uhlen M, Gallagher WM, Lundberg E, Pontén F (2013). A texture based pattern recognition approach to distinguish melanoma from non-melanoma cells in histopathological tissue microarray sections. PLoS One 8(5): e62070.

3. Joyce CW, Murphy IG, Rafferty M, Ryan D, McDermott EW, Gallagher WM. Tumor profiling using protein biomarker panels in malignant melanoma: application of tissue microarrays and beyond. Expert Rev Proteomics. 2012 Aug;9(4):415-23.

4. Lindsay CR, Lawn S, Campbell AD, Faller WJ, Rambow F, Mort RL, Timpson P, Li A, Cammareri P, Ridgway RA, Morton JP, Doyle B, Hegarty S, Rafferty M, Murphy IG, McDermott EW, Sheahan K, Pedone K, Finn AJ, Groben PA, Thomas NE, Hao H, Carson C, Norman JC, Machesky LM, Gallagher WM, Jackson IJ, Van Kempen L, Beermann F, Der C, Larue L, Welch HC, Ozanne BW, Sansom OJ. P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. Nat Commun. 2011 Nov 22;2:555.

5. Gremel G, Ryan D, Rafferty M, Lanigan F, Hegarty S, Lavelle M, Murphy I, Unwin L, Joyce C, Faller W, McDermott EW, Sheahan K, Ponten F, Gallagher WM. Functional and prognostic relevance of the homeobox protein MSX2 in malignant melanoma. Br J Cancer. 2011 Aug 9;105(4):565-74.

6. Agnarsdóttir M, Sooman L, Bolander A, Strömberg S, Rexhepaj E, Bergqvist M, Ponten F, Gallagher W, Lennartsson J, Ekman S, Uhlen M, Hedstrand H. SOX10 expression in superficial spreading and nodular malignant melanomas. Melanoma Res. 2010 Dec;20(6):468-78.

7. Faller WJ, Rafferty M, Hegarty S, Gremel G, Ryan D, Fraga MF, Esteller M, Dervan PA, Gallagher WM. Metallothionein 1E is methylated in malignant melanoma and increases sensitivity to cisplatin-induced apoptosis. Melanoma Res. 2010 Oct;20(5):392-400.

8. Ryan D, Rafferty M, Hegarty S, O'Leary P, Faller W, Gremel G, Bergqvist M, Agnarsdottir M, Strömberg S, Kampf C, Pontén F, Millikan RC, Dervan PA, Gallagher WM.
Topoisomerase I amplification in melanoma is associated with more advanced tumours and poor prognosis. Pigment Cell Melanoma Res. 2010 Aug;23(4):542-53.

9. Brennan DJ, O'Connor DP, Rexhepaj E, Pontén F, Gallagher WM. (2010). Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat Rev Cancer, 10(9):605-17.

10. Strömberg S, Agnarsdóttir M, Magnusson K, Rexhepaj E, Bolander A, Lundberg E, Asplund A, Ryan D, Rafferty M, Gallagher WM, Uhlen M, Bergqvist M, Ponten F. Selective expression of Syntaxin-7 protein in benign melanocytes and malignant melanoma. J Proteome Res. 2009 Apr;8(4):1639-46.

11. Gremel G, Rafferty M, Lau TY, Gallagher WM. Identification and functional validation of therapeutic targets for malignant melanoma. Crit Rev Oncol Hematol. 2009 Dec;72(3):194-214.